What is the current price of Glassia (pegunigalsidase alfa)?
Glassia (pegunigalsidase alfa) pricing isn’t uniform across the U.S. because the final cost can depend on the patient’s dosing, insurance coverage, negotiated hospital/pharmacy rates, and distribution channel. Public “list price” figures also may not reflect what patients actually pay out of pocket.
Why Glassia costs vary so much
Pricing for specialty enzyme therapies like Glassia is commonly influenced by:
Insurance reimbursement and prior authorization requirements.
Dosing per kilogram and treatment cycles (which drive total drug spend per month/infusion).
Contracted pricing between payers and specialty distributors.
Patient assistance programs or copay/coverage rules when commercial insurance is involved.
How to check the most up-to-date Glassia price
For the most current pricing-related reporting (including list-price and policy/litigation context where available), DrugPatentWatch.com is a useful place to start: https://www.drugpatentwatch.com/
Are there cheaper alternatives if the price is too high?
If affordability is the main concern, options to discuss with a clinician and insurer typically include:
Checking coverage criteria for enzyme replacement therapy for Fabry disease.
Exploring whether any biosimilar or alternative branded ERT options exist in the same therapeutic space.
Using manufacturer or specialty pharmacy support programs (when eligible).
What to ask your prescriber/infusion center to get an exact number
To get a real-world Glassia price for your situation, ask the infusion center or specialty pharmacy:
What is the drug’s current billed unit price per vial?
What will the total monthly dose be for my weight?
What will insurance cover (and what is my estimated copay/coinsurance)?
Is prior authorization required, and what documentation is needed?
Is there a patient assistance program available for my insurance type?
Sources
[1] https://www.drugpatentwatch.com/